As the survival of MM patients continues to improve, prospective long-term follow up data are required on impact of CHIP on survival and TMN, particularly in the current era of widespread use of anti-CD38 monoclonal antibody therapies (daratumumab and isatuximab) in the treatment of MM. The gene discussed is CD38; the disease is Miyoshi myopathy.